Literature DB >> 25078705

A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes.

Kurt A Swanson1, Kara Balabanis1, Yuhong Xie1, Yukti Aggarwal1, Concepción Palomo2, Vicente Mas2, Claire Metrick1, Hui Yang1, Christine A Shaw1, José A Melero2, Philip R Dormitzer1, Andrea Carfi3.   

Abstract

Respiratory syncytial virus (RSV) is the leading infectious cause of severe respiratory disease in infants and a major cause of respiratory illness in the elderly. There remains an unmet vaccine need despite decades of research. Insufficient potency, homogeneity, and stability of previous RSV fusion protein (F) subunit vaccine candidates have hampered vaccine development. RSV F and related parainfluenza virus (PIV) F proteins are cleaved by furin during intracellular maturation, producing disulfide-linked F1 and F2 fragments. During cell entry, the cleaved Fs rearrange from prefusion trimers to postfusion trimers. Using RSV F constructs with mutated furin cleavage sites, we isolated an uncleaved RSV F ectodomain that is predominantly monomeric and requires specific cleavage between F1 and F2 for self-association and rearrangement into stable postfusion trimers. The uncleaved RSV F monomer is folded and homogenous and displays at least two key RSV-neutralizing epitopes shared between the prefusion and postfusion conformations. Unlike the cleaved trimer, the uncleaved monomer binds the prefusion-specific monoclonal antibody D25 and human neutralizing immunoglobulins that do not bind to postfusion F. These observations suggest that the uncleaved RSV F monomer has a prefusion-like conformation and is a potential prefusion subunit vaccine candidate. Importance: RSV is the leading infectious cause of severe respiratory disease in infants and a major cause of respiratory illness in the elderly. Development of an RSV vaccine was stymied when a clinical trial using a formalin-inactivated RSV virus made disease, following RSV infection, more severe. Recent studies have defined the structures that the RSV F envelope glycoprotein adopts before and after virus entry (prefusion and postfusion conformations, respectively). Key neutralization epitopes of prefusion and postfusion RSV F have been identified, and a number of current vaccine development efforts are focused on generating easily produced subunit antigens that retain these epitopes. Here we show that a simple modification in the F ectodomain results in a homogeneous protein that retains critical prefusion neutralizing epitopes. These results improve our understanding of RSV F protein folding and structure and can guide further vaccine design efforts.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25078705      PMCID: PMC4178725          DOI: 10.1128/JVI.01225-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies.

Authors:  L J Calder; L González-Reyes; B García-Barreno; S A Wharton; J J Skehel; D C Wiley; J A Melero
Journal:  Virology       Date:  2000-05-25       Impact factor: 3.616

2.  Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion.

Authors:  L González-Reyes; M B Ruiz-Argüello; B García-Barreno; L Calder; J A López; J P Albar; J J Skehel; D C Wiley; J A Melero
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

3.  Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.

Authors:  Jason S McLellan; Man Chen; M Gordon Joyce; Mallika Sastry; Guillaume B E Stewart-Jones; Yongping Yang; Baoshan Zhang; Lei Chen; Sanjay Srivatsan; Anqi Zheng; Tongqing Zhou; Kevin W Graepel; Azad Kumar; Syed Moin; Jeffrey C Boyington; Gwo-Yu Chuang; Cinque Soto; Ulrich Baxa; Arjen Q Bakker; Hergen Spits; Tim Beaumont; Zizheng Zheng; Ningshao Xia; Sung-Youl Ko; John-Paul Todd; Srinivas Rao; Barney S Graham; Peter D Kwong
Journal:  Science       Date:  2013-11-01       Impact factor: 47.728

4.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

Authors:  S Johnson; C Oliver; G A Prince; V G Hemming; D S Pfarr; S C Wang; M Dormitzer; J O'Grady; S Koenig; J K Tamura; R Woods; G Bansal; D Couchenour; E Tsao; W C Hall; J F Young
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

5.  Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes.

Authors:  Jason S McLellan; Yongping Yang; Barney S Graham; Peter D Kwong
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

6.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

7.  Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.

Authors:  Kurt A Swanson; Ethan C Settembre; Christine A Shaw; Antu K Dey; Rino Rappuoli; Christian W Mandl; Philip R Dormitzer; Andrea Carfi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-17       Impact factor: 11.205

8.  Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

Authors:  Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham
Journal:  Science       Date:  2013-04-25       Impact factor: 47.728

9.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

10.  Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies.

Authors:  L J Anderson; P Bingham; J C Hierholzer
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

View more
  22 in total

1.  Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.

Authors:  Normand Blais; Martin Gagné; Yoshitomo Hamuro; Patrick Rheault; Martine Boyer; Ann-Muriel Steff; Guy Baudoux; Vincent Dewar; Josée Demers; Jean-Louis Ruelle; Denis Martin
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

2.  Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection.

Authors:  Amy S Espeseth; Pedro J Cejas; Michael P Citron; Dai Wang; Daniel J DiStefano; Cheryl Callahan; Gregory O' Donnell; Jennifer D Galli; Ryan Swoyer; Sinoeun Touch; Zhiyun Wen; Joseph Antonello; Lan Zhang; Jessica A Flynn; Kara S Cox; Daniel C Freed; Kalpit A Vora; Kapil Bahl; Andrew H Latham; Jeffrey S Smith; Marian E Gindy; Giuseppe Ciaramella; Daria Hazuda; Christine A Shaw; Andrew J Bett
Journal:  NPJ Vaccines       Date:  2020-02-14       Impact factor: 7.344

Review 3.  Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.

Authors:  Jason S McLellan
Journal:  Curr Opin Virol       Date:  2015-03-26       Impact factor: 7.090

4.  Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.

Authors:  Jorge C G Blanco; Lurds R Fernando; Wei Zhang; Arash Kamali; Marina S Boukhvalova; Lori McGinnes-Cullen; Trudy G Morrison
Journal:  J Virol       Date:  2019-11-13       Impact factor: 5.103

5.  Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels.

Authors:  Sandra Fuentes; Elizabeth M Coyle; Hana Golding; Surender Khurana
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

6.  The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion.

Authors:  Imogen M Bermingham; Keith J Chappell; Daniel Watterson; Paul R Young
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

Review 7.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

Review 8.  Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease.

Authors:  Patricio L Acosta; Mauricio T Caballero; Fernando P Polack
Journal:  Clin Vaccine Immunol       Date:  2015-12-16

9.  Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.

Authors:  Concepción Palomo; Vicente Mas; Michelle Thom; Mónica Vázquez; Olga Cano; María C Terrón; Daniel Luque; Geraldine Taylor; José A Melero
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

10.  Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F2 Subunit Are Critical for Its Fusion Activity.

Authors:  Stephanie N Hicks; Supranee Chaiwatpongsakorn; Heather M Costello; Jason S McLellan; William Ray; Mark E Peeples
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.